苑东生物：2025年度净利润2.83亿元，同比增长18.89%

Core Viewpoint - Yuan Dong Biotech (688513.SH) reported a slight decrease in total revenue for the fiscal year 2025, but achieved a significant increase in net profit, indicating effective management strategies in response to market challenges [1] Financial Performance - The company achieved total revenue of 1.331 billion yuan, a year-on-year decrease of 1.36% [1] - The net profit attributable to the parent company was 283 million yuan, reflecting a year-on-year increase of 18.89% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 206 million yuan, with a year-on-year growth of 18.01% [1] Operational Strategies - The slight decline in total revenue was influenced by the implementation of the tenth batch of national centralized procurement [1] - The company adopted multiple measures, including optimizing revenue structure, enhancing cost control, and improving operational efficiency, to mitigate the adverse effects of the procurement policy [1] - There was an increase in revenue from technical services and transfers, alongside a reduction in costs and expenses, contributing to stable profit growth [1]